<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302311</url>
  </required_header>
  <id_info>
    <org_study_id>101792</org_study_id>
    <nct_id>NCT04302311</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of Atrial Fibrillation in the Wait-Time Prior to Seeing a Cardiologist</brief_title>
  <acronym>CATCH-AF</acronym>
  <official_title>Early Diagnosis of Atrial Fibrillation in the Wait-Time Prior to Seeing a Cardiologist (CATCH-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Victoria Cardiac Arrhythmia Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Victoria Cardiac Arrhythmia Trials</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized patient-oriented trial to investigate whether continual symptomatic use of the
      Kardia Mobile monitoring device is a superior strategy for diagnosing Atrial Fibrillation
      (AF) in comparison to normal ambulatory monitoring with a 24-hour Holter monitor. Patients
      with referrals to an Electrophysiologist, symptoms of AF but no documentation of AF, and with
      at least one stroke risk factor based on the CHADS2 scoring system are randomized 1:1 to
      Kardia Mobile monitoring versus Holter monitoring alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to atrial fibrillation diagnosis compared between arms as analysed by Kaplan-Meier survival curves</measure>
    <time_frame>6 months</time_frame>
    <description>using the Log-rank test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation Paroxysmal</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Holter monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kardia/AliveCor monitoring with additional Holter monitoring as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Holter monitoring</intervention_name>
    <description>Use of smart device application and technologies to assess for arrhythmias</description>
    <arm_group_label>Enhanced Monitoring</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Atrial Fibrillation Diagnostic Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Kardia/AliveCor monitoring</intervention_name>
    <description>Kardia/AliveCor monitoring</description>
    <arm_group_label>Enhanced Monitoring</arm_group_label>
    <other_name>Atrial Fibrillation Diagnostic Testing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18

          -  Referral for episodic symptoms that may be due to arrhythmia (e.g. palpitations,
             dyspnea, or pre-syncope)

          -  At least one risk factor from CHADS-65 CCS Algorithm

        Exclusion Criteria:

          -  Previous diagnosis of atrial fibrillation

          -  Already anticoagulated for another diagnosis (e.g. metallic heart valve or pulmonary
             embolism)

          -  Symptoms typical of non-arrhythmic cause (e.g. exertional chest pain)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Sikkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Victoria Cardiac Arrhythmia Trials Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caitlin Patterson, BSC, CCRP</last_name>
    <phone>2505950400</phone>
    <phone_ext>1</phone_ext>
    <email>reception@catrials.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Patterson, BSC, CCRP</last_name>
      <phone>2505950400</phone>
      <phone_ext>1</phone_ext>
      <email>reception@catrials.org</email>
    </contact>
    <investigator>
      <last_name>Markus Sikkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrophysiology</keyword>
  <keyword>Holter monitoring</keyword>
  <keyword>Kardia/AliveCor</keyword>
  <keyword>Stroke risk factors</keyword>
  <keyword>Diagnosis of arrhythmias</keyword>
  <keyword>Smart device technology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

